Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry
Table 2
Effectiveness of antianemic treatments in German routine practice.
Operable solid tumor ()
Inoperable solid tumor ()
Hematological malignancy ()
Day 1 treatment
Transfusion
ESA
IV iron
ESA + IV iron
Transfusion
ESA
IV iron
ESA + IV iron
Transfusion
ESA
IV iron
ESA + IV iron
Hb(max) [g/dL]
78
41
18
11
257
79
71
27
67
34
7
5
Median
2.9
2.7
2.0
2.6
2.7
2.6
2.0
2.3
2.6
2.6
2.0
2.9
Mean ± StD
3.1 ± 1.5
3.0 ± 1.4
2.3 ± 1.2
2.8 ± 1.3
2.8 ± 1.8
2.8 ± 1.5
2.0 ± 1.6
2.5 ± 1.3
2.6 ± 1.5
2.5 ± 1.9
2.6 ± 1.5
2.8 ± 1.5
Hb(final) [g/dL]
63
40
16
11
223
77
67
26
62
32
7
5
Median
1.6
2.0
1.6
1.7
1.5
1.9
1.1
1.8
1.2
2.1
2.0
2.3
Mean ± StD
2.0 ± 1.8
2.1 ± 1.2
1.7 ± 1.5
2.1 ± 1.3
1.6 ± 1.5
2.1 ± 1.7
1.3 ± 1.5
1.9 ± 1.5
1.6 ± 1.8
1.9 ± 2.0
2.4 ± 1.6
2.2 ± 1.9
Responders
63
40
16
11
223
77
67
26
62
32
7
5
%
50.8
72.5
62.5
63.6
41.3
55.8
43.3
57.7
35.5
59.4
57.1
80.0
Transfusions
114
51
30
12
362
108
102
34
95
37
10
7
Weeks 1–4 [%]
100.0
25.5
13.3
8.3
100.0
26.9
16.7
17.6
100.0
29.7
10.0
—
Weeks 5–8 [%]
24.6
5.9
6.7
—
31.5
14.8
9.8
2.9
44.2
10.8
10.0
14.3
Weeks 9–12 [%]
17.5
3.9
3.3
—
26.2
8.3
7.8
5.9
33.7
21.6
20.0
—
Number of patients for whom variable is documented or could be calculated. The maximal difference between the baseline Hb and the highest Hb documented. The difference between the baseline Hb and the last Hb documented within the 12-week observation period, but at least 4 weeks after the start of treatment. A responder is defined as a patient with final Hb > 11 g/dL or with Hb(final) of ≥ 1.5 g/dL, with final Hb being the last documented Hb within the observation period, but at least 4 weeks after the start of antianemic treatment.
